Trends in the use of androgen deprivation in prostate cancer

Acta Oncologica

Volumn 43, Issue 4, 2004, Pages 382-387

  Salminen, Eeva K ^a   Wickström, Jan Erik ^a   Vahlberg, Tero ^b   Duchesne, Gillian M ^c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BICALUTAMIDE; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; HUMAN; ONCOLOGY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; UROLOGY;

ADULT; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; CHEMOTHERAPY, ADJUVANT; FINLAND; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; UROLOGY;

EID: 3042750782     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860410029500     Document Type: Article

References (20)

1. ESMO minimum clinical recommendation for use in prostate cancer. Ann Oncol 2003; 14: 1010-11.
2. Demers R, Tiwari A, Wei J, et al. Trends in utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer 2001; 92: 2309-17.
3. Gee WF. Practice trends in the diagnosis and management of prostate cancer in the USA. J Urol 1995; 154: 207-8.
4. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002; 360: 103-6.
5. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-46.
6. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52.
7. Potosky AL, Reeve B, Clegg L, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002; 94: 430-7.
8. Debruyne F. Hormonal therapy in prostate cancer. Semin Urol Oncol 2002; 20(3 Suppl.): 4-9.
9. Basaria S, Lieb II J, Tang A, et al. Long-term effects of androgen deprivation therapy in prostate cancer. Clin Endocrinol 2002; 56: 779-86.
10. Salminen E, Portin R, Korpela J, et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer 2003; 89: 971-6.
11. Duchesne G, Millar J, Moraga V, Rosenthal M, Royce P, Snow R. What to do for prostate cancer patients with a rising psa? - a survey of Australian practice. Int J Radiat Onc Biol Phys 2003; 55: 986-91.
12. Finnish Cancer Registry. Cancer statistics in Finland. Available at: http://www.cancer.fi
13. Oeflein MG. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol 2003; 169: 251-5.
14. Kirk D on behalf of the MRC Prostate Cancer Working Party Investigators Group. Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? (abstract) BJU International 2000; 86(Suppl. 3): 220.
15. Choo R, DeBoer G, Klotzt L, et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Rad Oncol Biol Phys 2001; 50: 615-20.
16. Taylor J, Griffith K, Sandler H. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Rad Oncol Biol Phys 2001; 50: 1212-9.
17. American Society for Therapeutic Radiation Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Rad Oncol Biol Phys 1997; 37: 1035-41.
18. Wei J, Dunn R, Sandler H, et al. PSA-free survival following radical prostatectomy, external beam radiation therapy or brachytherapy is associated with significant benefit in health related quality of life. J Urol 2000; 163: 337-8.
19. Padula G, Zelefsky M, Venkatranman E, et al. Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three dimensional conformal radiotherapy for prostate cancer. Int J Rad Oncol Biol Phys 2002; 52: 439-43.
20. Pickles T, Kim-Sing C, Morris J, Tyldesley S, Paltiel C. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Rad Oncol Biol Phys 2003; 57: 11-8.